No results for ‘’
Transgene Biotek Ltd
₹2.85
(2.89%)
Tue, 25 Aug 2026, 06:15 pm
Health Technology
Biotechnology
24.5KTransgene Biotek PB Ratio
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 292.69 | 97.62 | 72.26 | 54.80 | 298.96 | 528.57 | 17.04 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Price to book ratio | 2.11 | 1.10 | 0.61 | 0.19 | 0.98 | 0.70 | 0.69 | 0.04 | 0.18 | 0.08 | 0.08 | 0.23 | 0.30 | 0.69 | 0.70 | 1.56 | 1.57 | 1.66 | 5.76 | 2.53 |
| Price to sales ratio | 134 | 59.42 | 17.97 | 5.68 | 28.40 | 6.82 | 7.54 | 0.83 | 34.98 | 44.79 | 77.06 | 48.56 | 133.93 | 425.15 | 6380 | 204.68 | 315.51 | 342.50 | 262.57 | 97.36 |
| Price to cash flow ratio | 251.79 | 69.89 | 0 | 14.19 | 27.84 | 0 | 10.12 | 0.98 | 4.98 | 4.11 | 2.11 | 615.18 | 7.22 | 0 | 0 | 0 | 0 | 0 | 0 | 17.42 |
| Enterprise value | 241Cr | 133Cr | 85.31Cr | 34.19Cr | 128Cr | 84.94Cr | 219Cr | 34.85Cr | 46.89Cr | 28.84Cr | 28.89Cr | 29.59Cr | 25.58Cr | 39.34Cr | 33.09Cr | 46.01Cr | 39.35Cr | 31.98Cr | 75.67Cr | 39.62Cr |
| Enterprise value to EBITDA ratio | 1020 | 464.03 | 47.74 | 20.76 | 78.07 | 35.89 | 194.62 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt to equity ratio | 0.12 | 0.12 | 0.16 | 0.12 | 0.13 | 0.09 | 0.07 | 0.07 | 0.06 | 0.08 | 0.09 | 0.27 | 0.19 | 0.21 | 0.32 | 0.51 | 0.69 | 1.15 | 1.31 | 1.45 |
| Return on equity % | 0 | 1.14 | 0.85 | 0.33 | 0.33 | 0.08 | 4.41 | -0.64 | -50.54 | -9.63 | -11.78 | -17.03 | -11.57 | -18.31 | -28.73 | -38 | -52.51 | -41.80 | -5.94 | -6.52 |
Transgene Biotek Ltd Price to Book Ratio
The Transgene Biotek Ltd Price to Book Ratio is a key financial metric used by investors to evaluate Transgene Biotek Ltd's valuation, profitability, and overall financial performance. Tracking the Transgene Biotek Ltd Price to Book Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Transgene Biotek Ltd (NSE: , BSE: 526139) is currently trading at ₹2.85, with a market capitalization of ₹18.28Cr. As a leading company in the Health technology sector and Biotechnology industry, monitoring the Transgene Biotek Ltd Price to Book Ratio is essential for fundamental analysis.
Transgene Biotek Ltd Price to Book Ratio Current Value
The current Transgene Biotek Ltd Price to Book Ratio stands at 2.53.
The Transgene Biotek Ltd Price to Book Ratio has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Transgene Biotek Ltd Price to Book Ratio Historical Trend
The Transgene Biotek Ltd Price to Book Ratio has shown the following historical trend:
- 2024: 2.53
- 2023: 5.76
- 2022: 1.66
- 2021: 1.57
- 2020: 1.56
The decline in Transgene Biotek Ltd Price to Book Ratio indicates improving financial efficiency or better earnings growth.
What Transgene Biotek Ltd Price to Book Ratio Indicates for Investors
The Transgene Biotek Ltd Price to Book Ratio plays a crucial role in understanding the company's financial health and valuation.
The P/B ratio shows how the market values company assets relative to book value.
Transgene Biotek Ltd Price to Book Ratio Analysis Summary
The Transgene Biotek Ltd Price to Book Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Transgene Biotek Ltd Price to Book Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Transgene Biotek Ltd Price to Book Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.